"Unrelated Donors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Providers of tissues for transplant to non-related individuals.
| Descriptor ID |
D061349
|
| MeSH Number(s) |
M01.898.828
|
| Concept/Terms |
Unrelated Donors- Unrelated Donors
- Donor, Unrelated
- Unrelated Donor
- Donors, Unrelated
|
Below are MeSH descriptors whose meaning is more general than "Unrelated Donors".
Below are MeSH descriptors whose meaning is more specific than "Unrelated Donors".
This graph shows the total number of publications written about "Unrelated Donors" by people in this website by year, and whether "Unrelated Donors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Unrelated Donors" by people in Profiles.
-
Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT. Blood Adv. 2025 May 13; 9(9):2356-2365.
-
Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT. Transplant Cell Ther. 2025 Jan; 31(1):18.e1-18.e12.
-
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial. Am J Hematol. 2024 04; 99(4):785-788.
-
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
-
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 03; 29(3):208.e1-208.e6.
-
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplant Cell Ther. 2023 04; 29(4):267.e1-267.e5.
-
Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Transplantation. 2022 06 01; 106(6):1279-1287.
-
Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplant. 2022 02; 57(2):243-251.
-
Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations. Transplant Cell Ther. 2021 12; 27(12):968-972.
-
Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 11; 27(11):909.e1-909.e6.